{{Rsnum
|rsid=721048
|Gene=EHBP1
|Chromosome=2
|position=62904596
|Orientation=plus
|GMAF=0.1088
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=EHBP1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 25.7 | 73.5
| HCB | 0.0 | 5.8 | 94.2
| JPT | 0.9 | 12.4 | 86.7
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 12.3 | 87.7
| CHB | 0.0 | 5.8 | 94.2
| CHD | 0.0 | 5.5 | 94.5
| GIH | 2.0 | 21.8 | 76.2
| LWK | 0.0 | 3.7 | 96.3
| MEX | 1.7 | 27.6 | 70.7
| MKK | 0.6 | 20.5 | 78.8
| TSI | 2.0 | 24.5 | 73.5
| HapMapRevision=28
}}{{PMID|18264098|OA=1
}} shows a significantly stronger association with more aggressive forms of [[prostate cancer]] (odds ratios (OR) = 1.15; P = 7.7 x 10(-9)).

{{GWAS Summary
|SNP=rs721048
|PubMedID=18264098
|Condition=Prostate cancer
|Gene=EHBP1
|Risk Allele=A
|pValue=8.00E-009
|OR=1.15
|95CI=1.10-1.21
|OA=1
}}

{{omim
|desc=PROSTATE CANCER
|id=176807
|rsnum=721048
}}

{{omim
|desc=PROSTATE CANCER, HEREDITARY, X-LINKED 2; HPCX2
|id=300704
|rsnum=721048
}}

{{omim
|desc=PROSTATE CANCER, HEREDITARY, 12; HPC12
|id=611868
|rsnum=721048
}}

{{omim
|id=609922
|desc=EH DOMAIN-BINDING PROTEIN 1; EHBP1
|rsnum=721048
}}

{{PharmGKB
|RSID=rs721048
|Name_s=
|Gene_s=EHBP1
|Feature=
|Evidence=PubMed ID:18264098; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (Initial Sample Size: 1,854 cases, 21,372 controls; Replication Sample Size: 8,239 cases, 7,590 controls; Risk Allele: rs721048-A).
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356751
}}

{{PharmGKB
|RSID=rs721048
|Name_s=
|Gene_s=EHBP1
|Feature=
|Evidence=PubMed ID:18264098
|Annotation=This SNP on 2p15 was shown to be associated with prostate cancer in a genome-wide SNP association study on over 23,000 Icelanders, followed by a replication study including over 15,500 individuals from Europe and the United States.
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA161925610
}}

{{omim
|id=609922
|rsnum=721048
|variant=0001
}}

{{PMID Auto
|PMID=19104501
|Title=Prostate cancer genomics: towards a new understanding.
|OA=1
}}

{{PMID Auto
|PMID=19318432
|Title=Generalizability of associations from prostate cancer genome-wide association studies in multiple populations.
|OA=1
}}

{{PMID Auto
|PMID=19434657
|Title=Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
|OA=1
}}

{{PMID Auto
|PMID=19549807
|Title=Prostate cancer risk associated loci in African Americans.
|OA=1
}}

{{PMID Auto
|PMID=19567509
|Title=Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.
|OA=1
}}

{{PMID Auto
|PMID=20039378
|Title=Estimation of genotype relative risks from pedigree data by retrospective likelihoods.
|OA=1
}}

{{PMID Auto
|PMID=21390317
|Title=Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs721048
|overall_frequency_n=20
|overall_frequency_d=128
|overall_frequency=0.15625
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=23405784
|Title=[Susceptibility to prostate cancer in Han Chinese: single nucleotide polymorphism analysis of 1 667 cases]
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}